Used in cancer research and therapy development, particularly for targeting tumors that overexpress the insulin-like growth factor 1 receptor (IGF-1R). It has been investigated in clinical trials for solid tumors including pancreatic, lung, and sarcoma cancers. The antibody inhibits IGF-1R signaling, which plays a role in cell proliferation, survival, and metastasis. By blocking this pathway, it can suppress tumor growth and enhance the effects of chemotherapy and other targeted agents. Its high specificity makes it valuable as a reference standard in immunoassays and binding studies during drug development.